Huntington National Bank Has $497,000 Stock Position in Solventum Co. (NYSE:SOLV)

Huntington National Bank cut its position in Solventum Co. (NYSE:SOLV) by 19.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,523 shares of the company’s stock after selling 1,781 shares during the period. Huntington National Bank’s holdings in Solventum were worth $497,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SOLV. Modus Advisors LLC bought a new stake in shares of Solventum during the fourth quarter worth about $25,000. Stonebridge Financial Group LLC bought a new stake in Solventum during the 4th quarter worth approximately $26,000. Crews Bank & Trust purchased a new stake in shares of Solventum in the fourth quarter worth approximately $32,000. Synergy Asset Management LLC bought a new position in shares of Solventum in the fourth quarter valued at approximately $35,000. Finally, Spire Wealth Management purchased a new position in shares of Solventum during the fourth quarter valued at approximately $37,000.

Solventum Price Performance

Solventum stock opened at $66.22 on Friday. The business’s 50 day simple moving average is $75.42 and its 200 day simple moving average is $71.95. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a market cap of $11.45 billion and a price-to-earnings ratio of 24.08. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Ratings Changes

Several equities analysts have weighed in on SOLV shares. Bank of America raised their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley boosted their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group increased their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.